v3.22.2.2
Collaboration and License Agreements - Amgen, Inc. (Details)
$ in Thousands
12 Months Ended
Sep. 28, 2016
USD ($)
agreement
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jul. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Proceeds from the issuance of common stock   $ 0 $ 0 $ 250,479  
Revenues   243,231 138,287 $ 87,992  
Contract liabilities   74,099 111,055    
Amgen | Collaboration and License agreements          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Number of agreements | agreement 2        
Amgen | Olpasiran Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Cash received as due under collaboration agreement $ 35,000        
Proceeds from the issuance of common stock 21,500        
Milestone payments $ 30,000        
Amgen | Olpasiran Agreement | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Additional remaining development regulatory and sales milestones payments   400,000      
Amgen | Olpasiran and ARO-AMG1 Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Milestone payments         $ 20,000
Revenues   0 $ 0    
Contract liabilities   0      
Contract assets   $ 0